l'Ami MJ, et al. - An open-label, non-inferiority, randomised clinical trial is conducted to investigate whether patients with adalimumab concentrations >8 μg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity. Adalimumab-treated patients with rheumatoid arthritis (RA) with trough concentrations >8 μg/mL can prolong their standard dosing interval to once every 3 weeks without loss of disease control.